July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
A dual variable Markov model to assess the potential benefits of choroideremia gene therapy on quality adjusted life years (QALYs)
Author Affiliations & Notes
  • Celine-Lea Halioua-Haubold
    University of Oxford, Oxford, United Kingdom
  • Jasleen Jolly
    University of Oxford, Oxford, United Kingdom
  • Rafael Pinedo Villanueva
    University of Oxford, Oxford, United Kingdom
  • David Brindley
    University of Oxford, Oxford, United Kingdom
  • Robert E MacLaren
    University of Oxford, Oxford, United Kingdom
  • Footnotes
    Commercial Relationships   Celine-Lea Halioua-Haubold, Oisin Biotechnologies Inc (C); Jasleen Jolly, None; Rafael Pinedo Villanueva, None; David Brindley, Biolacuna Limited (I), IP Asset Ventures Limited (I), Translation Ventures Limited (I); Robert MacLaren, Choroideremia Research Foundation (F), Euretina (S), Nighstar Therapeutics Inc (I), Nighstar Therapeutics Inc (C), Nighstar Therapeutics Inc (E), Nighstar Therapeutics Inc (P), Nighstar Therapeutics Inc (F), Spark Therapeutics Inc (C), University of Oxford (E), University of Oxford (P)
  • Footnotes
    Support  SENS Research Foundation
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3897. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Celine-Lea Halioua-Haubold, Jasleen Jolly, Rafael Pinedo Villanueva, David Brindley, Robert E MacLaren; A dual variable Markov model to assess the potential benefits of choroideremia gene therapy on quality adjusted life years (QALYs). Invest. Ophthalmol. Vis. Sci. 2018;59(9):3897.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Gene therapy is currently the only therapeutic option for inherited retinal degenerations. Although the significant reimbursement costs of gene therapies may pose challenges for patient access, it needs to be balanced against the impact of sight loss. To investigate the benefit of retinal gene therapy, we estimated the potential quality of life impact of choroideremia (CHM) associated visual degeneration. CHM is an appropriate model of a gene therapy disease target: it has a young patient population, has no treatment, and invariably causes blindness, thereby having a severe impact on quality of life.

Methods : We built a lifetime Markov model of CHM-associated progressive visual degeneration. The impact of visual impairment on the patient was measured in quality-adjusted life-years (QALYs). In the hypothetical scenario, patients received either no treatment or the curative gene therapy, which was assumed to be 98% effective in halting degeneration in either one or both eyes when both eyes are treated. Three case studies were modeled: 20-year-old patients with preserved retinal area and visual acuity (P1); 45-year-olds who had significantly deteriorated retinal area but preserved visual acuity (P2); and 60-year-old patients who had both significantly deteriorated retinal area and reduced visual acuity (P3). The data were modelled on published natural history data of the disease. Patients who received successful gene therapy were assumed still to be at risk of visual impairment due to non-CHM disease or injury at population-wide rates.

Results : On the assumption that CHM patients receiving gene therapy showed significant retention of visual functionality over non-treated patients, subgroup P1 patients were estimated to gain a mean of 19.96 QALYs; for P2 the expected increase in quality of life was 6.68 QALYs, whereas for P3, gene therapy was associated with an expected gain of 4.43 QALYs.

Conclusions : In young adults in the earlier stages of the disease, successful gene therapy provides a significant increase in health-related quality of life that can be quantified. In pediatric patients, the impact may be higher. Even for older patients with very advanced degeneration, the gains are smaller but still present.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×